Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Rockwell Medical, Inc. to Present at Upcoming September Conferences

RMTI

WIXOM, Mich., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ: RMTI) ("Rockwell Medical" or the "Company") today announced that Stuart Paul, Chief Executive Officer, is scheduled to present at two upcoming conferences as follows: 

ConferenceNewsMakers in the Biotech Industry
Date:Friday, September 6, 2019
Time:2:10 P.M. Eastern Daylight Time
Location:Millennium Times Square New York, New York, NY
Webcast: http://media.rampard.com/newsmakers/rockwellmedical
  
ConferenceH.C. Wainwright 21st Annual Global Investment Conference
Date:Tuesday, September 10, 2019
Time:11:40 A.M. Eastern Daylight Time
Location:Lotte New York Palace Hotel, New York, NY
Webcast:http://wsw.com/webcast/hcw5/rmti/

The presentations will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.rockwellmed.com, under the “Investors” section.

To schedule a one-on-one meeting with management, please contact your H.C. Wainwright and/or NewsMakers representatives, or Lisa Wilson at lwilson@insitecony.com.

About Rockwell Medical
Rockwell Medical is a biopharmaceutical company dedicated to improving outcomes for patients with anemia, with an initial focus on end-stage renal disease (ESRD) and chronic kidney disease (CKD). Rockwell Medical's exclusive renal drug therapy, Triferic, supports disease management initiatives to improve the quality of life and care of dialysis patients and is intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. The Company has developed multiple formulations of Triferic: (1) Dialysate Triferic; and (2) I.V. Triferic. Dialysate Triferic is the only FDA-approved therapeutic indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. The Company’s strategy is to bring its therapeutics to market in the United States and to utilize partners to develop and commercialize such therapeutics in international markets. Rockwell Medical is also an established manufacturer, supplier and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. Please visit www.rockwellmed.com for more information.

Investor Relations:
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

Primary Logo